Collegium Pharma (COLL) Tops Q3 EPS by 37c ; Offers Guidance

Collegium Pharma (NASDAQ: COLL) reported Q3 EPS of $2.25, $0.37 better than the analyst estimate of $1.88. Revenue for the quarter came in at $209.36 million versus the consensus estimate of $190.12 million.

GUIDANCE:

Collegium Pharma sees FY2025 revenue of $775-785 million, versus the consensus of $751.6 million.

For earnings history and earnings-related data on Collegium Pharma (COLL) click here.

You May Also Be Interested In

• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• Boeing wins $121 million Navy contract for P-8A upgrades
• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings